|
| |
Illumina Launches the iScanT System
Next-Generation Genetic Analysis Platform Improves Sample Throughput
Sixfold
SAN DIEGO, April 14, 2008 -- Illumina, Inc. (NASDAQ:ILMN) today launched the
iScan System, a next-generation scanner that provides researchers conducting
genotyping and gene expression studies with significantly greater throughput,
enhanced automation, and improved ease of use. When used with the recently
launched Infinium® High-Density (HD) Human1M-Duo and Human610-Quad Genotyping
BeadChips, and Illumina’s laboratory information management systems and
automation options, the iScan System can complete genotyping studies up to six
times faster than studies run on Illumina’s BeadStation.
Under an Early Access Program, Illumina began shipping the iScan System in Q1
2008 to customers in both the academic and industrial sector. Among them were
Scripps Genomics Medicine and Translational Science Institute and Cogenics.
Cogenics is a division of Clinical Data and plans to use the iScan System to
bolster their services offerings. Illumina will commence broad commercial
shipment of the iScan System in Q2 2008.
“As our products become more complex, especially in the areas of high-density
genotyping, copy number variation analysis, and gene expression profiling, it is
important to have a scanner that keeps pace with the needs of genetic research,”
says Jay Flatley, President and Chief Executive Officer of Illumina. “The iScan
System offers researchers a next-generation microarray scanner that incorporates
higher-performance optics and detection technology. Using our multi-sample
iSelect™ BeadChip, researchers can process 120 samples in just 60 minutes,
producing results in record time. This directly translates into faster project
completion, faster study publication, and reduced study costs.”
Researchers at Scripps Genomics Medicine and Translational Science Institute are
using the iScan System along with the Human610-Quad BeadChips to identify
genetic determinants of cardiovascular disease towards more effective
diagnostics and preventive strategies for this global health problem. After
scanning fewer than 100 BeadChips, Scripps researchers have reported call rates
averaging 99.8 percent, which are consistent with Illumina’s existing high call
rates for the BeadStation.
The iScan System is a high-resolution scanner that supports rapid, sensitive,
and accurate imaging of Illumina’s BeadChip-based genetic analysis products.
Using sub-micron resolution, assay automation, and laboratory information
management systems options, researchers can produce up to 225 million genotypes
per day with one scanner. More information about the iScan System can be
obtained at www.illumina.com/iScan .
To facilitate a smooth transition for its existing customer base, as well as to
lower switching costs for others, Illumina is offering trade-in programs that
cater to the specific needs of various users.
About Infinium HD Genotyping
Illumina's genotyping products offer a flexible BeadChip design and HD
architecture. The Infinium HD Assay combined with the Infinium HD BeadChip
allows large-scale interrogation of variations in the human genome, accelerating
the ability of researchers to cost-effectively unlock the genetic basis of
disease. Infinium HD products provide a powerful complement to Illumina's
genotyping offering, which includes Infinium II, iSelect Infinium, GoldenGate®,
and VeraCode® genotyping products. For more information on Illumina's HD
genotyping products, please visit
www.illumina.com/dna .
About Illumina
Illumina ( www.illumina.com ) is a leading
developer, manufacturer, and marketer of next-generation life-science tools and
integrated systems for the large-scale analysis of genetic variation and
biological function. Using our proprietary technologies, we provide a
comprehensive line of products and services that currently serve the sequencing,
genotyping, and gene expression markets, and we expect to enter the market for
molecular diagnostics. Our customers include leading genomic research centers,
pharmaceutical companies, academic institutions, clinical research
organizations, and biotechnology companies. Our tools provide researchers around
the world with the performance, throughput, cost effectiveness, and flexibility
necessary to perform the billions of genetic tests needed to extract valuable
medical information from advances in genomics and proteomics. We believe this
information will enable researchers to correlate genetic variation and
biological function, which will enhance drug discovery and clinical research,
allow diseases to be detected earlier, and permit better choices of drugs for
individual patients.
“Safe Harbor” Statement under the Private Securities Litigation Reform Act
of 1995: this release may contain forward-looking statements that involve risks
and uncertainties. Among the important factors that could cause actual results
to differ materially from those in any forward-looking statements are Illumina’s
ability (i) to integrate effectively our recent acquisition of Solexa, Inc.,
(ii) to develop and commercialize further our BeadArray™, VeraCode®, and Solexa®
technologies and to deploy new sequencing, gene expression, and genotyping
products and applications for our technology platforms, (iii) to manufacture
robust microarrays and Oligator® oligonucleotides, (iv) to integrate and scale
our VeraCode technology, together with other factors detailed in our filings
with the Securities and Exchange Commission including our recent filings on
Forms 10-K and 10-Q or in information disclosed in public conference calls, the
date and time of which are released beforehand. We disclaim any intent or
obligation to update these forward-looking statements beyond the date of this
release.
# # #
CONTACT:
Media outside USA:
Katie Odgaard / Claire Mosley
College Hill
+44 (0) 20 7457 2020
illumina@collegehill.com
Media: Investors:
Maurissa Bornstein
Peter J. Fromen
Public Relations Manager
Sr. Director, Investor Relations
858.332.4055
858.202.4507
mbornstein@illumina.com
pfromen@illumina.com
| |
|
